Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15076060 | 0.99 | BRD4 (0.45) | BRD4POLBGRIN1GRIN2AGRIN2B | |
| SCHEMBL14129352 | 0.92 | BRD4 (0.47) | BRD4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10191056 | 0.90 | NAAA (0.52) | POLBMEN1KMT2ANAAANPC1 | |
| SCHEMBL15087658 | 0.89 | GRIN1 (0.42) | BRD4POLBGRIN1GRIN2AGRIN2B | |
| SCHEMBL14129503 | 0.87 | SMN1; SMN2 (0.45) | BRD4NAMPTMEN1KMT2ANPC1 | |
| SCHEMBL12173390 | 0.86 | BRD4 (0.46) | BRD4POLBNPC1RAB9A | |
| SCHEMBL16510003 | 0.86 | SMN1; SMN2 (0.47) | BRD4NAMPTMEN1KMT2ANPC1 | |
| SCHEMBL14129348 | 0.86 | SMN1; SMN2 (0.47) | BRD4NAMPTMEN1KMT2ANPC1 | |
| SCHEMBL10191159 | 0.85 | BRD4 (0.42) | BRD4POLBNAMPT | |
| SCHEMBL16360963 | 0.85 | HDAC1 (0.41) | POLBNAMPTNAAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216871-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | INVITROGEN CORPORATION | 2020-07-09 | — | — | US | disclosed |
| EP-2535423-B1 | Labeling and detection of nucleic acids | LIFE TECHNOLOGIES CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation | 2017-12-21 | — | — | US | disclosed |
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation | 2017-12-21 | — | — | US | disclosed |
| EP-2623986-B1 | Labeling and detection of post translationally modified proteins | LIFE TECHNOLOGIES CORP (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9645140-B2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2017-05-09 | — | — | US | disclosed |
| US-9645140-B2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2623609-B1 | Labeling and detection of post translationally modified proteins | LIFE TECHNOLOGIES CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20150051096-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation | 2015-02-19 | — | — | US | disclosed |
| US-20150051096-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation | 2015-02-19 | — | — | US | disclosed |
| US-20140336079-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | LIFE TECHNOLOGIES CORP (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2623610-A2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2623986-A2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2623609-A2 | Labeling and detection of post translationally modified proteins | Life Technologies Corporation (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120301894-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | Life Technologies Corporation (US) | 2012-11-29 | — | — | US | disclosed |
| US-8114636-B2 | Labeling and detection of nucleic acids | Life Technologies Corporation (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2224013-A1 | Methods for the determination of telomerase activity using click chemistry | Life Technologies Corporation (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20080050731-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070249014-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | INVITROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216871-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | BRD4 2235/4885POLB 3185/4885GRIN1 3522/4885 |
| US-20070249014-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | BRD4 2235/4885POLB 3185/4885GRIN1 3522/4885 |
| US-20170362624-A1 | LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS | PTMS, DNPEP, BTD | BRD4 2235/4885POLB 3185/4885GRIN1 3522/4885 |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | RNGTT, ADAR, ALKBH1 | BRD4 2111/4885POLB 159/4885GRIN1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.